China Pharma Holdings (CPHI) EBITDA Margin (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly EBITDA Margin came in at 150.98% in Q2 2026, down 8741.0% on a YoY basis from 1.75% in Q2 2025, and down 32.91% quarter-over-quarter from 113.6% in Q1 2026.
Powered by 
Analysis
China Pharma Holdings (CPHI) EBITDA Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has reported EBITDA Margin for 17 consecutive years, with 150.98% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 8741.0% year-over-year to 150.98%; the trailing twelve-month figure through Jun 2026 stood at 111.84% (down 2786.0% YoY), and the FY2025 full-year result was 78.16%, up 2317.0% from the prior year.
- EBITDA Margin retreated to 150.98% in Q2 2026 per CPHI's latest filing, from 113.6% in the prior quarter.
- Across five years, EBITDA Margin topped out at 20.28% in Q1 2023 and bottomed at 150.98% in Q2 2026.
- Historically, EBITDA Margin has averaged 74.11% across 5 years, with a median of 65.17% in 2025.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 10888 bps in 2024, then surged 8687 bps in 2025.
- Over 5 years, EBITDA Margin stood at 40.02% in 2022, then sank by 38 bps to 55.1% in 2023, then tumbled by 91 bps to 105.47% in 2024, then rose by 7 bps to 97.9% in 2025, then plunged by 54 bps to 150.98% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 150.98%, 113.6%, and 97.9% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 42.23% |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -150.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -150.98% |
| Mar 31, 2026 | -113.60% |
| Dec 31, 2025 | -97.90% |
| Sep 30, 2025 | -83.06% |
| Jun 30, 2025 | -63.57% |
| Mar 31, 2025 | -66.76% |
| Dec 31, 2024 | -105.47% |
| Sep 30, 2024 | -98.65% |
| Jun 30, 2024 | -150.44% |
| Mar 31, 2024 | -66.87% |
| Dec 31, 2023 | -55.10% |
| Sep 30, 2023 | -39.57% |
| Jun 30, 2023 | -41.56% |
| Mar 31, 2023 | -20.28% |
| Dec 31, 2022 | -40.02% |
| Sep 30, 2022 | -35.03% |
| Jun 30, 2022 | -48.33% |
| Mar 31, 2022 | -56.84% |
| Dec 31, 2021 | -22.45% |
| Sep 30, 2021 | -38.53% |